-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post earnings per share (EPS) of ($0.36) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.33). Oxford Immunotec Global posted earnings of ($0.22) per share during the same quarter last year, which suggests a negative year over year growth rate of 63.6%. The business is expected to issue its next earnings report on Tuesday, February 27th.

On average, analysts expect that Oxford Immunotec Global will report full year earnings of ($2.17) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($2.12). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.25) to ($1.02). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Oxford Immunotec Global.

A number of analysts recently weighed in on OXFD shares. BTIG Research started coverage on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 target price on the stock. Cowen restated a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global in a research report on Thursday, September 28th. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Piper Jaffray Companies reduced their price target on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. Finally, ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Oxford Immunotec Global has an average rating of “Hold” and a consensus price target of $19.75.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now directly owns 17,778 shares in the company, valued at $237,336.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.11% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its position in shares of Oxford Immunotec Global by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after purchasing an additional 1,500 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of Oxford Immunotec Global by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Oxford Immunotec Global by 9.1% during the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after purchasing an additional 2,053 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Oxford Immunotec Global by 5.4% during the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock worth $1,161,000 after purchasing an additional 3,507 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Oxford Immunotec Global by 6.8% during the second quarter. TIAA CREF Investment Management LLC now owns 76,094 shares of the company’s stock worth $1,280,000 after purchasing an additional 4,840 shares in the last quarter. Institutional investors own 89.35% of the company’s stock.

Oxford Immunotec Global (NASDAQ OXFD) traded down $0.22 during midday trading on Thursday, reaching $13.93. 284,400 shares of the company were exchanged, compared to its average volume of 263,350. The company has a market capitalization of $359.17, a PE ratio of -6.93 and a beta of -0.09. Oxford Immunotec Global has a twelve month low of $12.19 and a twelve month high of $19.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72.

ILLEGAL ACTIVITY NOTICE: “-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/04/0-36-eps-expected-for-oxford-immunotec-global-plc-oxfd-this-quarter.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply